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Phthalate esters (PE’s) are plasticizers used to soften PVC-based 
medical devices. PE’s are the most abundant man-made pollutants 
and increase the risk of developing an allergic respiratory disease 
or a malignancy.  The leaching of PE’s in donated packed red 
blood cells (PRBC) during storage was assessed. PRBC transfu-
sion bags containing CPD/AS-1 (ADSOL) buffer were analyzed. 
Samples were collected on storage day 1 and day 42. Two PE’s, 
di-(2-ethylhexyl)  phthalate  (DEHP)  and  mono-(2-ethylhexyl) 
phthalate  (MEHP),  were  measured  by  liquid  chromatography 
coupled to mass spectrometry (LCMS). Interleukin-8 (IL-8) was 
measured  by  standard  ELISA  techniques.  DEHP  significantly 
increased  from  34.3  μM  (±20.0  SD)  on  day  1  to  433.2  μM 
(±131.2 SD) on day 42, a 12.6-fold increase. Similarly, MEHP 
significantly increased from 3.7 μM (±2.8 SD) on day 1 to 74.0 
μM (±19.1 SD) on day 42, a 20.2-fold increase. Also, DEHP 
and MEHP increased the release of IL-8 from human umbilical 
vein  endothelial  cells  (HUVEC).  The  transfusion  of  older 
units of PRBC could lead to an accumulation of PE’s possibly 
resulting in inflammation and other effects. This accumulation 
could be exacerbated due to the decreased metabolism of PE’s 
since trauma patients have a lower esterase activity, the enzymes 
responsible for metabolizing PE’s. The effect of oxidative stress 
caused by PE’s is discussed as a potential mechanism for increases 
in inflammation caused by older units of PRBC.
Introduction
Phthalate esters are a group of plasticizers produced commer-
cially to impart flexibility to an otherwise rigid polyvinylchloride 
(PVC).1 PVC and phthalates are used extensively in the produc-
tion of blood collection bags and other medical devices. In 2002, 
more  than  18  billion  pounds  of  phthalates  were  used  in  the 
manufacturing of plastics worldwide.1 In particular, DEHP, the 
most commonly used plasticizer, accounted for over 20% of the 
total  phthalates  produced  annually.1  Consequently,  phthalates 
are widely distributed in the ecosystem and are among the most 
abundant man-made environmental pollutants. Although human 
urinary excretion levels are usually below exposure limit values of 
the  US  EPA  and  other  worldwide  environmental  agencies,  the 
cumulative chronic exposure to all phthalates and possible syner-
gistic endocrine effects need to be investigated.2
In the last 10 years, extensive laboratory studies have attempted 
to determine the impact of long-term phthalate exposure on human 
health. A metabolite of DEHP, MEHP, was shown to be carcino-
genic by activating two nuclear transcription factors, PPARα and 
PPARγ,  important  to  cell  differentiation.3  Additionally,  DEHP 
has  been  shown  to  be  a  developmental  and  reproductive  toxi-
cant  suspected  of  having  endocrine  disrupting  or  modulating 
effects.4 The development of some allergic respiratory diseases has 
been attributed to DEHP and MEHP with the former causing 
an increase in IgG and the latter promoting increased levels of 
pro-inflammatory cytokines such as interleukin-6 (IL-6) and inter-
leukin-8 (IL-8).5,6
Almost all toxicological studies of DEHP (Fig. 1A) and MEHP 
(Fig. 1B) only consider ingestion, inhalation and dermal exposure. 
These three exposure routes still have to undergo absorption to the 
bloodstream. In blood bags and other phthalate-containing medical 
devices, the absorption pathway is skipped due to the intravenous 
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administration of blood bag contents. Therefore, we measured the 
amount of DEHP and MEHP in the supernatants of packed red 
blood cell (PRBC) bags collected at a blood donation center using 
liquid  chromatography/mass  spectrometry  (LCMS)  techniques. 
Phthalate levels were measured on day 1 post-donation and day 
42 which is the expiration date for stored PRBC. Our results are 
discussed in relation to the deleterious health effects sometimes 
seen in the administration of older blood products.7 Also, a poten-
tial oxidative stress mechanism addressing the pro-inflammatory 
processes caused by DEHP and MEHP is proposed.
Results
Using  DEHP  and  MEHP  standards,  the  amount  of  each 
phthalate  ester  was  measured  in  the  day  1  and  day  42  super- 
natants  collected  from  PVC  bags  containing  donated  PRBC. 
DEHP (Fig. 2) and MEHP (Fig. 3) had retention times of 10.5 
and 7.4 minutes, respectively. Dissolving stocks of the standards 
in  acetonitrile  and  then  diluting  to  working  concentrations  in 
1X PBS did not significantly alter the retention times of either 
phthalate compared to the phthalate retention times observed in 
the sample supernatants. In addition to retention times, DEHP   
(Fig.  2)  and  MEHP  (Fig.  3)  were  identified  by  their  expected 
monoisotopic mass (M + H+) of 391.28 and 279.16, respectively. 
During the 42 day storage period, DEHP increased from 34.3 μM 
(±20.0  SD)  on  day  1  to  433.2  μM  (±131.2  SD)  on  day  42,   
a  12.6-fold  increase  (Fig.  4A).  This  is  visually  evident  when 
comparing  the  peak  heights  in  the  representative  mass  chro-
matograms for the day 1 sample (Fig. 2A) and day 42 sample   
(Fig.  2B).  Similarly,  MEHP  levels  increased  from  3.7  μM   
(±2.8 SD) to 74.0 μM (±19.1 SD), a 20.2-fold increase (Fig. 4B). 
Again, the MEHP increase can be observed when comparing the 
peak  heights  in  the  representative  mass  chromatograms  for  the   
day 1 sample (Fig. 3A) and day 42 sample (Fig. 3B).
To  assess  the  pro-inflammatory  potential  of  the  phthalate 
esters,  HUVEC  were  dosed  with  nanomolar  concentrations  of 
MEHP and DEHP. At almost all dosage concentrations used, both 
MEHP  and  DEHP  caused  significant  increases  in  IL-8  release 
(Fig. 5). With increasing MEHP concentrations, an increase in 
IL-8  release  was  observed.  However,  IL-8  release  decreased  as 
DEHP concentrations increased, but the amount of IL-8 release 
was still significantly higher than controls except for the 1,000 nM 
concentration. A concentration of greater than 1,000 nM DEHP 
caused significant decreases in IL-8 release accompanied by signifi-
cant decreases in HUVEC viability. For example, 100 μM DEHP 
caused a 60% decrease in IL-8 release with a corresponding 50% 
decrease in cell viability.
Discussion
Here,  we  show  the  leaching  of  the  plasticizer  DEHP  and 
MEHP from polyvinyl chloride (PVC) bags containing donated 
PRBC collected at a local blood bank. The initial levels of DEHP 
(34.3 μM) and MEHP (3.7 μM) correspond well with a previously 
published work that measured DEHP and MEHP concentrations 
ranging from 25–50 μM and 3–14 μM, respectively, in red blood 
cell concentrates.8 This previous work also observed a five-fold 
increase in DEHP levels over a 21-day storage period.8 In patients 
undergoing  hemodialysis  due  to  chronic  renal  failure,  a  high 
concentration of DEHP in blood was measured in these patients 
attributable  to  the  leaching  of  DEHP  from  the  hemodialysis 
tubing.9,10
In  human  plasma,  DEHP  is  rapidly  metabolized  by  ester 
hydrolysis to MEHP which is subsequently glucuronidated and 
excreted in urine.1,10 MEHP accumulation is of concern because 
MEHP is 20 times more toxic than DEHP in rats.11 Additionally, 
MEHP has a longer plasma half-life due to its ability to bind to 
serum proteins, specifically to human serum albumin.12,13 Due to 
its lipophilic characteristics, DEHP also exerts many biochemical 
effects such as decreasing its own metabolism by inhibiting serum 
arylesterase  activity  levels.14  Administering  blood  products  in 
phthalate-containing  bags,  especially  older  blood  products,  to 
trauma patients could have deleterious results due to the already 
decreased arylesterase activity levels found in plasma collected from 
these particular patients.15
The effect of DEHP and MEHP on IL-8 release from HUVEC 
was assessed. At nanomolar concentrations, both phthalate esters 
significantly increased IL-8 release from HUVEC. The concentra-
tions used in the cell culture experiment are comparable to the 
concentrations  of  the  phthalate  esters  measured  in  the  PRBC 
supernatants after accounting for dilution of the transfusion in 
the  circulation.  A  typical  PRBC  unit  contains  about  200  mL 
of erythrocytes suspended in about 50 mL preservation fluid.16 
Plasticizer levels in PRBC bags
Figure 1. Chemical structure of (A) DEHP and (B) MEHP.Plasticizer levels in PRBC bags
168 Oxidative Medicine and Cellular Longevity 2009; Vol. 2 Issue 3
exposure  to  DEHP  causes  significant  increases  in  markers  of 
oxidative stress in liver.17,18 Also, in urban adult populations,   
a direct correlation was observed between urinary oxidative stress 
biomarkers and the degree of MEHP exposure.19 In endothelial 
cells,  oxidative  stress  induces  the  release  of  IL-8  in  a  dose-
dependent manner.20,21 Therefore, it is conceivable that DEHP   
and/or MEHP cause the release of pro-inflammatory mediators 
such  as  IL-8  via  an  oxidative  stress  mechanism. This  theory 
is  further  supported  by  our  observation  that  the  presence  of 
an oxidative environment increases during storage time in the 
same PRBC transfusion bags in which we measured DEHP and 
MEHP levels.22
Since phthalate ester concentrations were only measured in the 
supernatants (i.e., preservation fluid) of PRBC units using our 
methodology, a 100-fold dilution in a transfused patient can be 
expected assuming a total blood volume of 5 liters. Therefore, after 
dilution in the circulation, transfusion of 42-day-old blood trans-
lates to plasma levels of 740 nM MEHP and 4,330 nM DEHP per 
unit of PRBC transfused based on our findings.
The exact biochemical mechanism that causes the release of 
IL-8 from endothelial cells treated with DEHP or MEHP was 
not determined in our model. There is supporting evidence that 
oxidative  stress  caused  by  DEHP  or  MEHP  exposure  results 
in pro-inflammatory events such as IL-8 release. For example, 
Figure 3. Representative mass chromatograms measuring MEHP detected in day 1 (A) and day 42 (B) supernatants collected from stored packed red 
blood cell (PRBC) units (N = 10). MEHP (RT = 7.4 min, [M + H+] = 279.16) was detected using prepared standards (1–100 μM). For each run, 10 μL 
of sample was injected onto a YMC-Pack Protein-RP HPLC column (Waters, Milford, MA) heated to 50°C. A 20 minute linear gradient from 10 to 
40% solvent B using water/0.1% trifluoroacetic acid (solvent A) and acetonitrile/0.1% trifluoroacetic acid (solvent B) was utilized with a flow rate of   
1 mL/min.
Figure 2. Representative mass chromatograms measuring DEHP detected in day 1 (A) and day 42 (B) supernatants collected from stored packed red 
blood cell (PRBC) units (N = 10). DEHP (RT = 10.5 min, [M + H+] = 391.28) was detected using prepared standards (1–1,000 μM). For each run,   
10 μL of sample was injected onto a YMC-Pack Protein-RP HPLC column (Waters, Milford, MA) heated to 50°C. A 20 minute linear gradient from   
10 to 40% solvent B using water/0.1% trifluoroacetic acid (solvent A) and acetonitrile/0.1% trifluoroacetic acid (solvent B) was utilized with a flow 
rate of 1 mL/min.www.landesbioscience.com Oxidative Medicine and Cellular Longevity 169
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Unfortunately, we did not measure 
DEHP and MEHP levels in the RBC 
pellet that could significantly contribute 
to the total amount of phthalate esters 
administered  to  a  patient.  Since  this 
study was part of a larger study, only the 
supernatants from the PRBC units were 
saved  for  this  study.  Approximately 
28% of available DEHP binds imme-
diately to sites in both the membrane 
and cytosol fractions of erythrocytes.23 
The  contribution  of  DEHP  bound 
to erythrocyte membranes to potential 
health hazards in transfused patients is 
currently unknown. If DEHP incorpo-
rates itself in the HUVEC membranes, 
then  that  could  partially  explain  the 
decrease in viability seen at micromolar 
concentrations of DEHP.
Utilizing  banked  blood  prod-
ucts in the critically ill is a common 
medical  practice  employed  world-
wide  for  obvious  beneficial  reasons. 
Infusion-related  risk  factors,  such  as 
transfusion-related  acute  lung  injury 
(TRALI)  and  other  inflammatory 
pathologies,  increase  proportionally 
with  the  age  of  the  infused  blood 
product.7 Here, we show an increase 
in  the  supernatant  concentrations  of 
the  phthalates  DEHP  and  MEHP 
in  bags  containing  PRBC  between 
storage day 1 and day 42. Due to our 
limited  access  to  the  storage  bags, 
we were unable to monitor the accu-
mulation  of  the  phthalate  esters  on 
a  daily  basis.  This  would  determine 
whether  phthalate  accumulation  is  a 
linear progression or reaches a critical 
point that allows for the exponential 
increase  in  phthalate  concentrations. 
In the future, a clinical study corre-
lating  DEHP  and/or  MEHP  plasma 
levels  with  the  development  of  pro-
inflammatory based pathologies in the 
critically ill could be interesting. Based 
on  our  study,  we  suggest  that  the 
transfusion of older units of PRBC in 
trauma patients could lead to an accu-
mulation of DEHP and MEHP. Due 
to the known biochemical actions of 
DEHP and MEHP, this accumulation 
could  possibly  result  in  pro-inflam-
matory and other effects in transfused 
patients.
Figure  4.  Total  (A)  DEHP  and  (B)  MEHP  in  day  1  and  day  42  supernatants  collected  from  stored   
packed  red  blood  cell  (PRBC)  units  (N  =  10).  DEHP  and  MEHP  levels  were  quantitated  by  liquid   
chromatography/mass spectrometry (LCMS) analysis. For each run, 10 μL of sample was injected onto 
a YMC-Pack Protein-RP HPLC column (Waters, Milford, MA) heated to 50°C. A 20 minute linear gradi-
ent from 10 to 40% solvent B using water/0.1% trifluoroacetic acid (solvent A) and acetonitrile/0.1% 
trifluoroacetic  acid  (solvent  B)  was  utilized  with  a  flow  rate  of  1  mL/min.  Data  are  expressed  in   
micromolar (μM) concentrations. An asterisk (*) designates significance where p < 0.05 compared to 
day 1 supernatants (student t-test). Significant increases in DEHP and MEHP release from the PRBC bags 
were observed in the day 42 samples compared with the day 1 samples.Plasticizer levels in PRBC bags
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(+ESI-TOF  MS,  LCT,  Micromass,  UK)  using  a  method   
described previously.24 Ten μL of each sample was injected onto 
a YMC-Pack Protein-RP HPLC column (Waters, Milford, MA) 
heated to 50°C. A 20 minute linear gradient from 10 to 40% B 
using water/0.1% trifluoroacetic acid (A) and AcN/0.1% TFA (B) 
was utilized with a flow rate of 1 mL/min. The stock solutions   
for the DEHP (1–1,000 μM) and MEHP (1–100 μM) standards 
were  initially  dissolved  in  acetonitrile  and  then  diluted  in  1X 
phosphate-buffered saline (PBS) to working concentrations. Both 
DEHP and MEHP were obtained from Sigma-Aldrich (St. Louis, 
MO). A student t-test was used to compare day 1 versus day 42 
data to test for significant differences (p < 0.05, Microsoft Excel). 
All graphical data was generated using Matlab R14 (Mathworks, 
Natick, MA).
IL-8 release from HUVEC. The effect of DEHP and MEHP   
on  IL-8  release  from  HUVEC  was  investigated.  HUVEC  cells 
(Cambrex, Walkersville,  MD)  were  plated  on  48-well  plates  in 
endothelial growth medium-2 (EGM-2) containing 2% fetal calf 
serum (FCS), hydrocortisone, human fibroblast growth factor B, 
vascular endothelial growth factor, recombinant insulin-like growth 
factor-1, ascorbate, human epithelial growth factor, gentamycin 
Materials and Methods
Sample collection. Samples evaluated were obtained as part 
of a storage/leukoreduction study for PRBC. In brief, 10 whole 
blood  units  collected  in  citrate-phosphate-dextrose  (CPD)/
AS-1 (ADSOL) buffer were obtained from healthy adult blood 
donors by standard techniques and stored for 24 hours at 4°C. 
Packed red cells were prepared from whole blood by centrifuga-
tion of whole blood units at 4,200 rpm for 5 minutes. AS-1 
buffer from a satellite bag was added to the main packed red 
cell bag according to standard procedure. Packed red cell units 
were subsequently stored for 42 days at 4–6°C in accordance 
with American Association of Blood Banks standards. Sample 
supernatants were collected from PRBC on storage days 1 and 
42 by centrifugation at 1,000 g at 4°C for 10 minutes. A second 
centrifugation at 12,000 g was performed to remove membrane 
vesicles from stored cells. All samples were stored at -80°C until 
further analysis.
LCMS analysis. Sample supernatants were analyzed by HPLC 
(Waters  2795  Separations  Module,  Milford,  MA)  coupled  to 
positive electrospray ionization time of flight mass spectrometry 
Figure 5. Effect of DEHP and MEHP on IL-8 release in HUVEC. HUVEC were grown to near confluency (>90%) in 48-well plates in endothelial growth 
medium-2 (EGM-2) containing 2% fetal calf serum, hydrocortisone, human fibroblast growth factor B, vascular endothelial growth factor, recombinant 
insulin-like growth factor-1, ascorbate, human epithelial growth factor, gentamycin and heparin. HUVEC were treated with media only (control), DEHP, or 
MEHP for 24 hours in duplicate. An IL-8 ELISA was performed on the 24-hour supernatants. Data are expressed as % IL-8 release increase versus control 
wells. An asterisk (*) designates significance where p < 0.05 compared to control wells (student t-test). At 10, 100 and 1,000 nM MEHP, a significant 
increase in IL-8 release was observed. At 10 and 100 nM DEHP, a significant increase in IL-8 release was observed. This indicates the potential pro-
inflammatory capability of older units of stored packed red blood cells (PRBC).www.landesbioscience.com Oxidative Medicine and Cellular Longevity 171
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and heparin (all obtained from Cambrex) and allowed to grow to 
>90% confluency at 37°C, 5% CO2. Prior to addition of peptides, 
all wells were rinsed once with EGM-2 medium which did not 
contain ascorbate and FCS, but did contain all the growth factors 
and was supplemented with 1X insulin-transferrin-sodium selenite 
(ITSS, Sigma, St. Louis, MO). The cells were treated in duplicate 
(N = 3) with 10, 100 or 1,000 nM DEHP or MEHP, and the   
cells  were  incubated  for  24  hours  at  37°C,  5%  CO2.  After 
the  24-hour  incubation,  the  supernatants  were  collected.  The 
concentration  of  IL-8  in  each  supernatant  was  determined  by 
ELISA (Pierce Biotechnology, Rockford, IL) using a microplate 
reader (Molecular Devices, M2 Microplate Reader, SpectraMax®, 
Sunnyvale,  CA)  set  at  450  nm  with  a  570  nm  background   
subtraction.  Data  is  expressed  as  %  change  in  IL-8  release 
compared to controls ± standard deviation (N = 3), and statistical 
differences from controls (p < 0.05) were assessed using Student 
t-test (Microsoft Excel).
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